On 12/10/24, Esperion Therapeutics Inc (NASDAQ: ESPR) stock suffered a major decline of -20.6%, closing at $3.04. Moreover, trading volume in this decline was exceptionally high at 271% of normal. The stock has performed in line with the market over the last nine months and has declined -1.9% during the last week.
Current PriceTarget Research Rating
Esperion Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment